Evogene Ltd. (EVGN)

Market Cap	8.12M -12.8%
Revenue (ttm)	3.85M -30.9%
Net Income	-8.49M
EPS	-1.08
Shares Out	9.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,935
Open	0.8050
Previous Close	0.7806
Day's Range	0.7603 - 0.8450
52-Week Range	0.7200 - 2.4200
Beta	1.08
Analysts	Strong Buy
Price Target	3.50 (+327.35%)
Earnings Date	May 20, 2026

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: EVGN
• Website: https://www.evogene.com

Financial Performance

In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.

Analyst Summary

According to one analyst, the rating for EVGN stock is "Strong Buy" and the 12-month stock price target is $3.5.

Price Target

$3.5

(327.35% upside)

Analyst Consensus: Strong Buy